Cost effectiveness of Clopidogrel in the secundary prevention of major cardiovascular events;Die wirtschaftlichkeit von Clopidogrel in der kardiovaskulären sekundär-prävention: Eine kosten-effektivitäts-analyse auf der grundlage der caprie-studie

Praxis

Volumn 90, Issue 13, 2001, Pages 539-545

  Haldemann, R ^a,c   Luscher T F ^b   Szucs, T D ^b  

^a PharmaMedicus GmbH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Universitätsspital Zürich ^*  (Switzerland)

Author keywords

Clopidogrel; Cost effectiveness; Ischemic events; Platelet aggregation inhibitors; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; HEART INFARCTION; HUMAN;

ADULT; AGED; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SWITZERLAND; TICLOPIDINE;

EID: 0035967141     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Das Gesundheitswesen Schweiz: Leistungen, Kosten, Preise. Pharma Information, 2000, Basel.
2. Pharma-Markt Schweiz. Pharma Information, 2000, Basel.
3. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischeamic events (CAPRIE). Lancet 1996;348:1329-1339.
4. Beck-JR et al. A convenient approximation of life expectancy - the DEALE II. Use in medical decision-making. Am J Med 1982;73:889-897.
5. Bundesamt für Statistik. Neuchâtel: Statistik Schweiz 2000,14:Gesundheit. http://www.statistik_admin.ch/stat_ch.
6. Tengs-TO, Adams-ME, Pliskin-JS. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995;15:369-390.
7. Mason-J, Drummond-M, Torrance-G. Some guidelines on the use of cost effectiveness league tables. BMJ 1993,306:570-572.
8. Mark-DB, Hlatky-MA, Califf-RM et ak. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-1424.
9. Hay-JW, Yu-WM, Ashraf-T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999; 15(1): 47-74.
10. Szucs-TD, Gutzwiller-F. Kosten-Effektivität der Cholesterinsenkung in der koronaren Sekundärprävention in der Schweiz: eine Untersuchung auf der Grundlage der Scandinavian Simvastatin Survival Studie (4S-Sludie). Kardiovaskuläre Medizin 1998;1:45-56.
11. Scandinavian simvastatine survival study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatine survival study (4S). Lancet 1994;344:1383-1389.
12. Grover-SA, Coupal-L, Paquet-S, Zowall-H. Cost-effetiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor in the secondary prevention of cardiovascular disease. Arch Int Med 1999;159:593-600.